Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trial.

Distler O, Allanore Y, Denton CP, Kuwana M, Matucci-Cerinic M, Pope JE, Atsumi T, Bečvář R, Czirják L, Hachulla E, Ishii T, Ishikawa O, Johnson SR, De Langhe E, Stagnaro C, Riccieri V, Schiopu E, Silver RM, Smith V, Steen V, Stevens W, Szücs G, Truchetet ME, Wosnitza M, Laapas K, Kramer F, Khanna D

Open source

DOI: 10.1016/s2665-9913(23)00238-2
Published: 2023 Nov
Container: The Lancet. Rheumatology
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2665-9913-23-00238-2,
  title = {Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trial.},
  author = {Distler O and Allanore Y and Denton CP and Kuwana M and Matucci-Cerinic M and Pope JE and Atsumi T and Bečvář R and Czirják L and Hachulla E and Ishii T and Ishikawa O and Johnson SR and De Langhe E and Stagnaro C and Riccieri V and Schiopu E and Silver RM and Smith V and Steen V and Stevens W and Szücs G and Truchetet ME and Wosnitza M and Laapas K and Kramer F and Khanna D},
  year = {2023},
  journal = {The Lancet. Rheumatology},
  doi = {10.1016/s2665-9913(23)00238-2},
  url = {https://doi.org/10.1016/s2665-9913(23)00238-2}
}

RIS

TY  - JOUR
TI  - Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trial.
AU  - Distler O
AU  - Allanore Y
AU  - Denton CP
AU  - Kuwana M
AU  - Matucci-Cerinic M
AU  - Pope JE
AU  - Atsumi T
AU  - Bečvář R
AU  - Czirják L
AU  - Hachulla E
AU  - Ishii T
AU  - Ishikawa O
AU  - Johnson SR
AU  - De Langhe E
AU  - Stagnaro C
AU  - Riccieri V
AU  - Schiopu E
AU  - Silver RM
AU  - Smith V
AU  - Steen V
AU  - Stevens W
AU  - Szücs G
AU  - Truchetet ME
AU  - Wosnitza M
AU  - Laapas K
AU  - Kramer F
AU  - Khanna D
PY  - 2023
JO  - The Lancet. Rheumatology
DO  - 10.1016/s2665-9913(23)00238-2
UR  - https://doi.org/10.1016/s2665-9913(23)00238-2
ER  -

APA

O, D., Y, A., CP, D., M, K., M, M., JE, P., T, A., R, B., L, C., E, H., T, I., O, I., SR, J., E, D. L., C, S., V, R., E, S., RM, S., V, S., V, S., W, S., G, S., ME, T., M, W., K, L., F, K., & D, K. (2023). Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trial.. The Lancet. Rheumatology. https://doi.org/10.1016/s2665-9913(23)00238-2

Source records

pubmed · retrieved 2026-09-27T00:41:50.816Z
europe-pmc · retrieved 2026-09-27T00:41:50.832Z